2-(4-morpholinoanilino)-6-cyclohexylaminopurine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Jiang, M; Li, C; Li, J; Liang, D; Liu, J; Sun, W; Wang, S; Yang, X; Zhang, C; Zhang, M; Zhou, X | 1 |
1 review(s) available for 2-(4-morpholinoanilino)-6-cyclohexylaminopurine and ER-Negative PR-Negative HER2-Negative Breast Cancer
Article | Year |
---|---|
Molecular design and anticancer activities of small-molecule monopolar spindle 1 inhibitors: A Medicinal chemistry perspective.
Topics: Antineoplastic Agents; Cell Cycle Proteins; Drug Design; Drug Resistance; Humans; M Phase Cell Cycle Checkpoints; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Spindle Apparatus; Structure-Activity Relationship; Triple Negative Breast Neoplasms | 2019 |